Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oncology and hematology

J E Karp1, S Broder

  • 1National Cancer Institute, Bethesda, Md.

JAMA
|June 1, 1994
PubMed
Summary
This summary is machine-generated.

Overexpression of PTK-encoding oncogenes and ras drives many cancers. Targeting ras-based pathways offers a potential strategy for cancer therapy and prevention.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.

Cell death and differentiation·2015
Same author

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.

Leukemia·2011
Same author

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.

Leukemia·2010
Same author

Induction of acute lymphocytic leukemia differentiation by maintenance therapy.

Leukemia·2007
Same author

Fluorescent in situ hybridization (FISH) in bone marrow and peripheral blood of leukemia patients: implications for occupational surveillance.

Mutation research·2007
Same author

JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.

Leukemia·2006

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Protein tyrosine kinase (PTK)-encoding oncogenes and ras are frequently overexpressed or altered in various cancers.
  • These genetic alterations are key drivers in the development of epithelial and lymphohematopoietic malignancies.
  • Signal transduction pathways involving ras proteins play a crucial role in cell growth and proliferation.

Purpose of the Study:

  • To highlight the significance of PTK-encoding oncogenes and ras in cancer development.
  • To identify ras-based pathways as a potential molecular target for therapeutic intervention.
  • To explore the implications of targeting these pathways for cancer prevention.

Main Methods:

  • Review of existing literature on oncogene and ras pathway dysregulation in cancer.

Related Experiment Videos

  • Analysis of the role of signal transduction in malignant neoplasm evolution.
  • Identification of therapeutic strategies targeting molecular pathways.

    • Main Results:

    • Net overexpression or derangements of PTK-encoding oncogenes and ras are critical drivers in numerous cancers.
    • Ras-based signaling pathways are implicated in the progression of both epithelial and lymphohematopoietic cancers.
    • The study underscores the oncogenic potential of these molecular alterations.

    Conclusions:

    • Impeding signal transduction through ras-based pathways presents a promising molecular target.
    • Targeting ras pathways could offer a broad therapeutic strategy for various cancers.
    • This approach holds potential for both cancer therapy and prevention.